United States Biotechnology & Medical Research

Maravai LifeSciences Holdings Inc (MRVI)

Track

Over the past 90 days, Maravai LifeSciences Holdings Inc. has seen insider activity exclusively involving sales. General Counsel Kurt Oreshack executed five planned and proposed transactions totaling $635,500 in sales. This activity follows a period of significant stock price appreciation of 62.9% and a positive earnings report in May 2026 where the company beat EPS expectations.
Ticker: MRVI Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Maravai LifeSciences Holdings Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 10 Jun 2026
Value US$4,921,791.95 | Price 347.43 | Shares 70,567 (-15.8%)
Planned sale 10 Jun 2026
Value US$4,868,389.62 | Price 249.80 | Shares 15,066 (+5.8%)
Proposed sale 10 Jun 2026
Value US$127,500.00 | Price 5.10 | Shares 25,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
70,567 -15.8%
347.43
US$4,921,792 		70,567 -15.8% 347.43 US$4,921,792
2026-06-10 2026-06-10 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
15,066 +5.8%
249.80
US$4,868,390 		15,066 +5.8% 249.80 US$4,868,390
2026-06-10 2026-06-10 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
94,319
196.15
US$1,490,647 		94,319 196.15 US$1,490,647
2026-06-10 2026-06-09 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
25,000 -6.5%
5.06
US$126,500 		25,000 -6.5% 5.06 US$126,500
2026-06-09 2026-06-09 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
25,000
5.06
US$126,500 		25,000 5.06 US$126,500
2025-12-23 2025-12-23 PrS Proposed sale
3.2
PRAHALAD MURALI

Former Director

Non-Executive Director
3,951
3.33
US$13,138 		3,951 3.33 US$13,138
2025-12-19 2025-12-19 PrS Proposed sale
3.2
Hopfield Jessica

Former Director

Non-Executive Director
53,951
3.48
US$187,526 		53,951 3.48 US$187,526
2025-12-09 2025-12-08 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
48,528 +45.5%
3.67
US$178,098 		48,528 +45.5% 3.67 US$178,098
2025-12-09 2025-12-05 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
51,472 +93.4%
3.70
US$190,446 		51,472 +93.4% 3.70 US$190,446
2025-11-17 2025-11-13 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
216,212 +86.3%
3.25
US$702,689 		216,212 +86.3% 3.25 US$702,689
2025-11-13 2025-11-12 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
93,358 +59.4%
3.21
US$299,679 		93,358 +59.4% 3.21 US$299,679
2025-11-13 2025-11-11 B Purchase
2.4
Brust Bernd

Chief Executive Officer

Executive Director
157,201 +inf%
3.24
US$509,331 		157,201 +inf% 3.24 US$509,331
2025-01-31 2025-01-31 PrS Proposed sale
3.2
ORESHACK KURT

Officer

Officer
25,000
5.03
US$125,750 		25,000 5.03 US$125,750
2025-01-31 2025-01-31 PlS Planned sale
3.2
ORESHACK KURT

General Counsel

Officer
25,000 -13.0%
5.03
US$125,750 		25,000 -13.0% 5.03 US$125,750
2024-11-14 2024-11-12 B Purchase
0.7
DeFord John A
Non-Executive Director
17,500 +33.3%
5.75
US$100,625 		17,500 +33.3% 5.75 US$100,625
2024-11-12 2024-11-11 B Purchase
2.6
HULL CARL

See Remarks

Executive Director
175,000 +inf%
5.64
US$987,000 		175,000 +inf% 5.64 US$987,000
2024-05-30 2024-05-28 S Sale
3.2
GTCR INVESTMENT XI LLC
Non-Executive Director Large shareholder
9,940,974 -33.0%
9.82
US$97,570,660 		9,940,974 -33.0% 9.82 US$97,570,660
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings 2, LLC

Owner
1,531,028
10.78
US$16,504,482 		1,531,028 10.78 US$16,504,482
2024-05-28 2024-05-28 PrS Proposed sale
Maravai Life Sciences Holdings, LLC

Owner
8,409,946
10.78
US$90,659,218 		8,409,946 10.78 US$90,659,218
2020-11-30 2020-11-25 B Purchase
2.6
HULL CARL

Chief Executive Officer

Executive Director
35,000 +inf%
26.94
US$942,900 		35,000 +inf% 26.94 US$942,900
2020-11-25 2020-11-24 B Purchase
3.2
SELLERS LISA

See Remarks

Officer
18,888 +inf%
27.00
US$509,976 		18,888 +inf% 27.00 US$509,976
2020-11-25 2020-11-24 B Purchase
3.2
GRAY SUSANNAH
Non-Executive Director
20,000 +168.7%
27.00
US$540,000 		20,000 +168.7% 27.00 US$540,000
2020-11-25 2020-11-24 B Purchase
3.2
PRAHALAD MURALI
Non-Executive Director
18,000 +151.9%
27.00
US$486,000 		18,000 +151.9% 27.00 US$486,000
2020-11-25 2020-11-24 B Purchase
3.2
Hance Robert B
Non-Executive Director
10,000 +84.4%
27.00
US$270,000 		10,000 +84.4% 27.00 US$270,000
2020-11-25 2020-11-24 B Purchase
3.2
Hopfield Jessica
Non-Executive Director
50,000 +421.9%
27.00
US$1,350,000 		50,000 +421.9% 27.00 US$1,350,000
2020-11-25 2020-11-24 B Purchase
2.4
LUCIER GREGORY T
Non-Executive Director
15,000 +126.6%
27.00
US$405,000 		15,000 +126.6% 27.00 US$405,000
2020-11-25 2020-11-24 B Purchase
3.2
ORESHACK KURT

General Counsel

Officer
7,500 +inf%
27.00
US$202,500 		7,500 +inf% 27.00 US$202,500
Explore more

More insider trading research around Maravai LifeSciences Holdings Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America